Industry News
Pharmaceutical Industry News
Sun Pharma has launched an…
Sun Pharma has launched an eye-opening awareness push about a common—and commonly overlooked—complication of diabetes.
Pfizer and manufacturer Tris…
Pfizer and manufacturer Tris Pharma were accused in 2023 of previously providing ADHD med Quillivant through the Texas Medicaid program despite knowing that the drug failed quality control tests during production.
After months of back-and-forth…
After months of back-and-forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing option for the eye disease drug.
Cdymax Pharma has been slapped…
Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, India-based API maker, both linked to testing shortfalls.
New Gene-Editing Strategy Could Help Development of Treatments for Rare Diseases
Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases.
Bayer’s Hyrnuo is catching up to…
Bayer's Hyrnuo is catching up to Boehringer Ingelheim's rival Hernexeos with an accelerated approval to treat a rare tumor type in certain patients with non-small cell lung cancer.
With a $140 million investment,…
With a $140 million investment, Moderna will build a new facility at its manufacturing campus in Norwood, Massachusetts. The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA
Antheia is teaming up with…
Antheia is teaming up with TAPI—Teva’s active pharmaceutical ingredient and contract manufacturing business—in a bid to further commercialize its pipeline of biosynthetic drug ingredients and key start materials.
Novartis expect the expansion in…
Novartis expect the expansion in North Carolina will add 700 new employees to its ranks. The manufacturing campus will span some 700,000 square feet between new and existing space, Novartis said.
Agios’ shares nosedived by 49%…
Agios’ shares nosedived by 49% on Wednesday morning after the company revealed mixed phase 3 results for Pyrukynd in sickle cell disease.
Two months after Celltrion bought…
Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for $330 million, the South Korean biosimilar specialist said it will spend another 700 billion won ($478 million) to upgrade the plant.
¿Qué son los ensayos clínicos y cómo funcionan?
Una periodista del New York Times explica qué son, por qué son importantes y cómo nos ayudan a entender mejor la medicina.
Una píldora para la libido femenina se convierte en un momento cultural
Hace una década, Cindy Eckert tenía dificultades para convencer a los escépticos sobre un medicamento para la premenopausia. Últimamente, su negocio está en auge.
Alkermes and Avadel have reached…
Alkermes and Avadel have reached an accord on a new offer that would see Alkermes pay up to $22.50 per Avadel share to acquire the company. Both drugmakers’ boards have blessed the amended deal and
Teva Pharmaceutical is launching…
Teva Pharmaceutical is launching its first global innovation platform, challenging startups to submit novel strategies to tackle seven industry hurdles that run the gamut from manufacturing to R&D.
With a fresh FDA endorsement for…
With a fresh FDA endorsement for its drug plozasiran, Pasadena-based Arrowhead Pharmaceuticals has successfully broken through to the commercial realm.
The bankruptcy reorganization plan…
The bankruptcy reorganization plan will deliver $7.4 billion to creditors, including an up-to-$7 billion contribution from the Sackler family, while Purdue Pharma will dissolve into a new company called Knoa Pharma.
The distinction is important…
The distinction is important because under Avadel's existing transaction agreement with Alkermes, the latter company now has five business days to "discuss or negotiate in good faith" any potential amendments to its prior offer.
Positive results from a…
Positive results from a proof-of-concept study evaluating Merck’s Winrevair pave the way for further study of the activin signaling inhibitor as a potential treatment for a subset of heart failure patients.
Monday, the FDA’s Office of…
Monday, the FDA’s Office of Prescription Drug Promotion posted a new untitled letter dated Sept. 23 and addressed to AstraZeneca.